GST HG141
Alternative Names: GST-HG141Latest Information Update: 19 Mar 2025
At a glance
- Originator Fujian Cosunter Pharmaceutical
- Class Antivirals
- Mechanism of Action Capsid protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B
Most Recent Events
- 03 Jan 2023 Phase-II clinical trials in Hepatitis B (Treatment-experienced) in China (PO) (NCT05637541)
- 22 Jun 2022 Phase-II clinical trials in Hepatitis B (Combination therapy) in China (PO) as of June 2022
- 22 Jun 2022 Final pharmacodynamics and adverse events data from a phase I trial in Hepatitis B presented at the International Liver Congress 2022 (ILC-2022)